{
    "root": "27ad9395-c6d2-f500-ab18-07278b7c7b0e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Bortezomib",
    "value": "20250506",
    "ingredients": [
        {
            "name": "Bortezomib",
            "code": "69G8BD63PP"
        },
        {
            "name": "mannitol",
            "code": "3OWL53L36A"
        }
    ],
    "indications": "Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )",
    "contraindications": "For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. ( 2.1 , 2.10 ) The recommended starting dose of bortezomib for injection is 1.3 mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. ( 2.2 , 2.4 , 2.6 ) Retreatment for Multiple Myeloma: May retreat starting at the last tolerated dose. ( 2.6 ) Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment. ( 2.8 ) Dose must be individualized to prevent overdose. ( 2.10 )",
    "warningsAndPrecautions": "Bortezomib for Injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder. \n                  NDC 72603-270-01\n                  3.5 mg single-dose vial \n                  Unopened vials may be stored at 20째C to 25째C (68째F to 77째F) [see USP Controlled Room Temperature]. Retain in original package to protect from light. \n                  Follow guidelines for handling and disposal for hazardous drugs, including the use of gloves and other protective clothing to prevent skin contact1.",
    "adverseReactions": "Bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [seeAdverse Reactions (6.1)]. \n                  Bortezomib for injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib for injection."
}